Biopharmaceuticals · us
Tau Pathway Crosses the Phase 2 Signal Threshold; Diranersen’s Next Question Is Whether It Can Withstand the Enlarged Test of Phase 3
Biogen presented detailed Phase 2 CELIA data at AAIC, allowing Alzheimer’s disease treatment to see another possible path beyond amyloid beta. But the lowest dose was the most striking, while intrathecal administration and long-term benefit mean the Phase 3 trial will not only confirm efficacy, but also measure the boundaries of this scientific hypothesis.
In recent years, Alzheimer’s disease drug development has largely centered on amyloid beta, while tau protein has been like another lesion long suspected, but one that has been difficult to translate into a clear clinical victory. Biogen presented Phase 2 CELIA trial data for diranersen at the 2026 Alzheimer’s Association International Conference, held in London and online, bringing this pathway back to the threshold of late-stage development.
According to data released by Biogen, this antisense oligonucleotide drug reduced total tau in cerebrospinal fluid by about 50% to 65% in patients with early Alzheimer’s disease, and also lowered tau pathology signals in the brain. The Alzheimer’s Association also described the data as among the first evidence from a Phase 2 clinical trial showing that a drug can remove toxic tau tangles from the brains of patients with early Alzheimer’s disease.
The CELIA trial enrolled about 400 participants; Biogen’s trial registry data list the actual enrollment as 416 people, aged 50 to 80, diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. Participants were assigned to receive different doses of diranersen or placebo. The drug was administered by injection into the cerebrospinal fluid, making it different from current anti-amyloid antibodies in both mechanism and treatment burden.
The clinical signals require more cautious interpretation than the biomarkers. Biogen said diranersen showed a trend toward slowing clinical decline across multiple prespecified measures. The Alzheimer’s Association abstract noted that tau reductions were seen at the tested doses in both Phase 1 and Phase 2, and that multiple scales showed a consistent direction toward slower decline. However, reports and conference materials also indicated that the strongest response appeared at the lowest dose. This unintuitive dose-response relationship will become a central issue that the Phase 3 design must address.
Safety will also determine how far this path can go. The Associated Press reported that common adverse events with diranersen included injection-site pain and temporary confusion, and that the brain inflammation signals often discussed with anti-amyloid drugs have not been seen so far. These differences may become part of its clinical positioning, but using intrathecal administration to treat a chronic neurodegenerative disease still means patient selection, medical resources, and long-term acceptance cannot be judged by efficacy numbers alone.
External experts also leaned toward conditional optimism on the data. The Associated Press cited dementia researchers who were not involved in the study as saying that if tau targeting can be validated clinically, it would add an important piece beyond the amyloid pathway. But the Phase 2 trial’s size, follow-up time, and dose response are still insufficient to answer whether the drug can steadily alter the course of the disease. Biogen said it will advance Phase 3 development, and diranersen has not yet been approved by the U.S. FDA or other regulators.
Background Context
The focus of this announcement is not simply “tau reduction,” but the fact that biomarkers and clinical scales have moved closer together for the first time in a mid-stage trial. In the past, tau drugs often lost the connection among clearing pathology, improving symptoms, and trial design. Diranersen gives late-stage research a reason to keep asking questions, while also making the question more stringent: if tau truly is a modifiable driver of early Alzheimer’s disease, the Phase 3 trial must prove that this change can translate into measurable differences in patients’ daily function and the pace of cognitive decline.